bioMerieux (OTCMKTS:BMXMF) Given Average Rating of “Reduce” by Brokerages

bioMerieux (OTCMKTS:BMXMF) has received an average rating of “Reduce” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company.

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Piper Sandler assumed coverage on shares of bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Zacks Research raised shares of bioMerieux to a “hold” rating in a report on Tuesday, April 28th. UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Finally, Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday.

bioMerieux Price Performance

BMXMF opened at $78.00 on Tuesday. The firm’s fifty day moving average price is $87.83 and its 200 day moving average price is $107.46. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08. bioMerieux has a 12-month low of $77.00 and a 12-month high of $152.00.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.